Literature DB >> 15142389

Fluoxetine in depressed AUD adolescents: a 1-year follow-up evaluation.

Jack R Cornelius1, Oscar G Bukstein, Ihsan M Salloum, Thomas M Kelly, D Scott Wood, Duncan B Clark.   

Abstract

The authors conducted the first naturalistic 1-year follow-up evaluation of 10 adolescents with comorbid major depressive disorder and an alcohol use disorder (AUD) who had previously participated in an acute phase study of open-label fluoxetine plus psychotherapy (Cornelius et al. 2001). The goal of this follow-up evaluation was to determine whether the decreases in drinking and in depressive symptoms that were noted during the acute phase study persisted at the follow-up evaluation. At the 1-year follow-up evaluation, the group continued to demonstrate significantly fewer depressive symptoms (according to the 24-item Hamilton Rating Scale for Depression) and a lower frequency of drinking (drinking days in the last 30 days) than they had demonstrated at the baseline of the acute phase study. Surprisingly, all of the subjects had chosen to discontinue their antidepressant medication by the second month of their naturalistic follow-up period. Three subjects had experienced a relapse of their major depression during the follow-up period, and three others demonstrated a persistence of their original depressive episode throughout the follow-up period. Also, the number of drinks per drinking day continued to be high (about five per day), which was not significantly different from the baseline level. Thus, the long-term therapeutic effects of an acute phase trial of fluoxetine plus psychotherapy were limited. The high rate of recurrence or persistence of major depression in our sample and in a previous sample of nonalcoholic adolescents with major depression (Emslie et al. 1998) and the significant levels of drinking of our comorbid adolescents suggest that longer term treatment may be needed for at least some adolescents with major depressive disorder and alcohol use disorder.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15142389     DOI: 10.1089/104454604773840463

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  7 in total

Review 1.  Neurobiological processes in adolescent addictive disorders.

Authors:  Ty S Schepis; Bryon Adinoff; Uma Rao
Journal:  Am J Addict       Date:  2008 Jan-Feb

Review 2.  Pharmacotherapy of alcoholism in patients with co-morbid psychiatric disorders.

Authors:  Benjamin I Goldstein; Artemis Diamantouros; Ayal Schaffer; Claudio A Naranjo
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  LONGER-TERM EFFECTIVENESS OF CBT IN TREATMENT OF COMORBID AUD/MDD ADOLESCENTS.

Authors:  Jack R Cornelius; Antoine B Douaihy; Levent Kirisci; Dennis C Daley
Journal:  Int J Med Biol Front       Date:  2013

4.  Evaluation of cognitive behavioral therapy/motivational enhancement therapy (CBT/MET) in a treatment trial of comorbid MDD/AUD adolescents.

Authors:  Jack R Cornelius; Antoine Douaihy; Oscar G Bukstein; Dennis C Daley; Scott D Wood; Thomas M Kelly; Ihsan M Salloum
Journal:  Addict Behav       Date:  2011-04-09       Impact factor: 3.913

5.  The efficacy of two adolescent substance abuse treatments and the impact of comorbid depression: results of a small randomized controlled trial.

Authors:  Daniel A Santisteban; Maite P Mena; Joan Muir; Brian E McCabe; Clara Abalo; Amanda M Cummings
Journal:  Psychiatr Rehabil J       Date:  2015-03

6.  Combined MI + CBT for Depressive Symptoms and Binge Drinking Among Young Adults: Two Case Studies.

Authors:  Paola Pedrelli; Brian Borsari; Kathleen M Palm; Elizabeth Dalton; Maurizio Fava
Journal:  J Cogn Psychother       Date:  2013-08-01

7.  Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder.

Authors:  Jack R Cornelius; Oscar G Bukstein; D Scott Wood; Levent Kirisci; Antoine Douaihy; Duncan B Clark
Journal:  Addict Behav       Date:  2009-03-12       Impact factor: 3.913

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.